These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29515256)

  • 21. Human equilibrative nucleoside transporter 1 (hENT1) predicts the Asian patient response to gemcitabine-based chemotherapy in pancreatic cancer.
    Xiao JC; Zhang TP; Zhao YP
    Hepatogastroenterology; 2013; 60(122):258-62. PubMed ID: 23574652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy.
    Morinaga S; Nakamura Y; Watanabe T; Mikayama H; Tamagawa H; Yamamoto N; Shiozawa M; Akaike M; Ohkawa S; Kameda Y; Miyagi Y
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S558-64. PubMed ID: 21913012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.
    Tsujie M; Nakamori S; Nakahira S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Anticancer Res; 2007; 27(4B):2241-9. PubMed ID: 17695509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer.
    Elebro J; Ben Dror L; Heby M; Nodin B; Jirström K; Eberhard J
    Acta Oncol; 2016; 55(3):286-96. PubMed ID: 26362587
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic Value of Excision Repair Cross-Complementing Gene 1, Dihydropyrimidine Dehydrogenase, and Human Equilibrative Nucleotide Transporter 1 Expression and Their Implications for Adjuvant Treatment in Patients With Ampullary Carcinoma.
    Kawabata Y; Nishi T; Kidani A; Tajima Y
    Pancreas; 2015 Aug; 44(6):937-44. PubMed ID: 25906447
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
    Sierzega M; Pach R; Kulig P; Legutko J; Kulig J
    Pancreas; 2017; 46(5):684-689. PubMed ID: 28196013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TGF-β-induced stromal CYR61 promotes resistance to gemcitabine in pancreatic ductal adenocarcinoma through downregulation of the nucleoside transporters hENT1 and hCNT3.
    Hesler RA; Huang JJ; Starr MD; Treboschi VM; Bernanke AG; Nixon AB; McCall SJ; White RR; Blobe GC
    Carcinogenesis; 2016 Nov; 37(11):1041-1051. PubMed ID: 27604902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Progress in pancreatic cancer: moving beyond gemcitabine?
    Basu B; Jodrell D
    Expert Rev Anticancer Ther; 2012 Aug; 12(8):997-1000. PubMed ID: 23030218
    [No Abstract]   [Full Text] [Related]  

  • 29. hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic review.
    Nordh S; Ansari D; Andersson R
    World J Gastroenterol; 2014 Jul; 20(26):8482-90. PubMed ID: 25024604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.
    Spratlin J; Sangha R; Glubrecht D; Dabbagh L; Young JD; Dumontet C; Cass C; Lai R; Mackey JR
    Clin Cancer Res; 2004 Oct; 10(20):6956-61. PubMed ID: 15501974
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial.
    Wang-Gillam A; Li CP; Bodoky G; Dean A; Shan YS; Jameson G; Macarulla T; Lee KH; Cunningham D; Blanc JF; Hubner RA; Chiu CF; Schwartsmann G; Siveke JT; Braiteh F; Moyo V; Belanger B; Dhindsa N; Bayever E; Von Hoff DD; Chen LT;
    Lancet; 2016 Feb; 387(10018):545-557. PubMed ID: 26615328
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of thymidine phosphorylase and orotate phosphoribosyltransferase mRNA expression and its ratio to dihydropyrimidine dehydrogenase in the prognosis and clinicopathological features of patients with pancreatic cancer.
    Miyake K; Imura S; Yoshizumi T; Ikemoto T; Morine Y; Shimada M
    Int J Clin Oncol; 2007 Apr; 12(2):111-9. PubMed ID: 17443278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human Equilibrative Nucleoside Transporter 1 Expression in Endoscopic Ultrasonography-Guided Fine-Needle Aspiration Biopsy Samples Is a Strong Predictor of Clinical Response and Survival in the Patients With Pancreatic Ductal Adenocarcinoma Undergoing Gemcitabine-Based Chemoradiotherapy.
    Yamada R; Mizuno S; Uchida K; Yoneda M; Kanayama K; Inoue H; Murata Y; Kuriyama N; Kishiwada M; Usui M; Ii N; Tsuboi J; Tano S; Hamada Y; Tanaka K; Horiki N; Ogura T; Shiraishi T; Takei Y; Katayama N; Isaji S
    Pancreas; 2016; 45(5):761-71. PubMed ID: 26784908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer.
    Eto K; Kawakami H; Kuwatani M; Kudo T; Abe Y; Kawahata S; Takasawa A; Fukuoka M; Matsuno Y; Asaka M; Sakamoto N
    Br J Cancer; 2013 Apr; 108(7):1488-94. PubMed ID: 23492684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human equilibrative nucleoside transporter 1 expression predicts survival of advanced cholangiocarcinoma patients treated with gemcitabine-based adjuvant chemotherapy after surgical resection.
    Kobayashi H; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Ann Surg; 2012 Aug; 256(2):288-96. PubMed ID: 22580938
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II, open-label, multicenter study to evaluate the antitumor efficacy of CO-1.01 as second-line therapy for gemcitabine-refractory patients with stage IV pancreatic adenocarcinoma and negative tumor hENT1 expression.
    Li D; Pant S; Ryan DP; Laheru D; Bahary N; Dragovich T; Hosein PJ; Rolfe L; Saif MW; LaValle J; Yu KH; Lowery MA; Allen A; O'Reilly EM
    Pancreatology; 2014; 14(5):398-402. PubMed ID: 25278310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine-cisplatin-based combination chemotherapy.
    Matsumura N; Nakamura Y; Kohjimoto Y; Inagaki T; Nanpo Y; Yasuoka H; Ohashi Y; Hara I
    BJU Int; 2011 Jul; 108(2 Pt 2):E110-6. PubMed ID: 21166756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma.
    Borbath I; Verbrugghe L; Lai R; Gigot JF; Humblet Y; Piessevaux H; Sempoux C
    Eur J Cancer; 2012 May; 48(7):990-6. PubMed ID: 22137164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
    Neoptolemos JP; Stocken DD; Bassi C; Ghaneh P; Cunningham D; Goldstein D; Padbury R; Moore MJ; Gallinger S; Mariette C; Wente MN; Izbicki JR; Friess H; Lerch MM; Dervenis C; Oláh A; Butturini G; Doi R; Lind PA; Smith D; Valle JW; Palmer DH; Buckels JA; Thompson J; McKay CJ; Rawcliffe CL; Büchler MW;
    JAMA; 2010 Sep; 304(10):1073-81. PubMed ID: 20823433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
    Soong R; Shah N; Salto-Tellez M; Tai BC; Soo RA; Han HC; Ng SS; Tan WL; Zeps N; Joseph D; Diasio RB; Iacopetta B
    Ann Oncol; 2008 May; 19(5):915-9. PubMed ID: 18245778
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.